213 related articles for article (PubMed ID: 20369307)
1. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
Griffith C; Zhang S; Mukhopadhyay S
Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
[TBL] [Abstract][Full Text] [Related]
2. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
3. Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.
Fibbi B; Pinzani P; Salvianti F; Rossi M; Petrone L; De Feo ML; Panconesi R; Vezzosi V; Bianchi S; Simontacchi G; Mangoni M; Pertici M; Forti G; Pupilli C
Endocr Pathol; 2014 Sep; 25(3):324-31. PubMed ID: 24858900
[TBL] [Abstract][Full Text] [Related]
4. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation.
Papi G; Corrado S; Pomponi MG; Carapezzi C; Cesinaro A; LiVolsi VA
Endocr Pathol; 2003; 14(3):269-76. PubMed ID: 14586073
[TBL] [Abstract][Full Text] [Related]
5. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
7. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
8. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
[TBL] [Abstract][Full Text] [Related]
9. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
[TBL] [Abstract][Full Text] [Related]
10. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules.
Musholt TJ; Fottner C; Weber MM; Eichhorn W; Pohlenz J; Musholt PB; Springer E; Schad A
World J Surg; 2010 Nov; 34(11):2595-603. PubMed ID: 20652698
[TBL] [Abstract][Full Text] [Related]
11. Medullary Thyroid Carcinoma Associated with Germline RET
Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism.
Rotondi M; Ercolino T; Fonte R; Lagonigro MS; Leporati P; Villani L; La Manna L; Mannelli M; Chiovato L
J Endocrinol Invest; 2009 Feb; 32(2):115-8. PubMed ID: 19411807
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
14. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation.
Vantyghem MC; Pigny P; Leteurtre E; Leclerc L; Bauters C; Douillard C; D'Herbomez M; Carnaille B; Proye C; Wemeau JL; Lecomte-Houcke M
Thyroid; 2004 Oct; 14(10):842-7. PubMed ID: 15588381
[TBL] [Abstract][Full Text] [Related]
15. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
16. Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation.
Machens A; Lorenz K; Weber F; Dralle H
Eur J Surg Oncol; 2021 Apr; 47(4):920-923. PubMed ID: 32962888
[TBL] [Abstract][Full Text] [Related]
17. Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A; Lorenz K; Weber F; Dralle H
Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
[TBL] [Abstract][Full Text] [Related]
18. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
19. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
20. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.
Fazioli F; Piccinini G; Appolloni G; Bacchiocchi R; Palmonella G; Recchioni R; Pierpaoli E; Silvetti F; Scarpelli M; Bruglia M; Melillo RM; Santoro M; Boscaro M; Taccaliti A
Thyroid; 2008 Jul; 18(7):775-82. PubMed ID: 18631007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
